ALT - Company ID 0001326190
The table below shows Altimmune, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | $5.00K | $5.00K | $5.00K | $5.00K | $5.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $16.19M | $14.96M | $17.24M | $15.83M | $19.80M | $21.16M |
Altimmune, Inc. reported annual revenue of $41.00K for fiscal year 2025. That is up 105.0% from $20.00K in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $3.24M (FY 2016) to $41.00K. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $8.05M |
| $5.90M |
| $5.69M |
| $5.99M |
| $4.97M |
| $5.59M |
| Operating income | -$24.24M | -$20.86M | -$22.92M | -$21.82M | -$24.77M | -$26.75M |
| Income tax | - | - | - | -$681.00K | $0.00 | $0.00 |
| Net income | -$22.56M | -$19.01M | -$22.15M | -$19.57M | -$22.84M | -$24.64M |
| EPS (diluted) | -$0.18 | -$0.21 | -$0.27 | -$0.26 | -$0.32 | -$0.35 |